Welcome to our dedicated page for Constellation Pharmaceuticals news (Ticker: CNST), a resource for investors and traders seeking the latest updates and insights on Constellation Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Constellation Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Constellation Pharmaceuticals's position in the market.
Constellation Pharmaceuticals (Nasdaq: CNST) has announced an underwritten public offering of 4,000,000 shares of its common stock, with a 30-day option for underwriters to purchase an additional 600,000 shares. The offering is subject to market conditions and will be executed under an effective shelf registration statement filed on December 9, 2019. J.P. Morgan, Jefferies, Cowen, and RBC Capital Markets are managing the offering. The detailed terms will be outlined in a prospectus supplement to be filed with the SEC.
Constellation Pharmaceuticals (Nasdaq: CNST) presented new data on CPI-0610 at the European Hematology Association meeting, showing promising results in treating myelofibrosis. In a clinical trial, 73% of first-line patients had a 35% spleen volume reduction at 12 weeks. Notably, the drug also displayed potential disease-modifying effects, increasing hemoglobin levels and converting some transfusion-dependent patients to transfusion independence. The company plans to prioritize further development of CPI-0209 based on insights from its trials.
Constellation Pharmaceuticals (Nasdaq: CNST) announced its participation in the Goldman Sachs 41st Annual Global Healthcare Conference on June 11, 2020, at 8:00 AM EDT. CEO Jigar Raythatha will present, and a live audio webcast will be available on the company’s Investor Relations website. The presentation will be archived for 30 days post-event. Constellation focuses on developing novel therapeutics that target gene expression to treat serious medical needs in cancer patients, including its BET inhibitor CPI-0610 and EZH2 inhibitors CPI-1205 and CPI-0209.
Constellation Pharmaceuticals (Nasdaq: CNST) will participate in the Jefferies Virtual Healthcare Conference on June 2, 2020, at 2:30 PM EDT. CEO Jigar Raythatha will present, and a live audio webcast will be accessible on the company’s investor relations website. The replay will be available for 30 days post-event. Constellation focuses on developing epigenetic therapeutics to address unmet medical needs in cancer treatment, particularly through its BET inhibitor CPI-0610 and EZH2 inhibitors CPI-1205 and CPI-0209.
Constellation (NASDAQ: CNST) will host a virtual analyst/investor event on June 12 at 8:00 AM EDT to discuss data from the MANIFEST clinical trial for CPI-0610 at the European Hematology Association meeting. The agenda includes an overview of myelofibrosis and the potential impact of CPI-0610, alongside a review of the clinical trial data. The MANIFEST trial focuses on myelofibrosis treatment using CPI-0610, evaluating its effects in various patient cohorts. This event will be webcast live, providing an opportunity for investors to engage in a Q&A session.
Constellation Pharmaceuticals (Nasdaq: CNST) reported promising results from its MANIFEST clinical trial of CPI-0610 for myelofibrosis. Key findings include a 72% rate of spleen volume reduction (SVR35) at 12 weeks and 67% at 24 weeks in first-line patients. The trial also observed improvements in total symptom scores and bone marrow fibrosis. Data from approximately 50 first-line and 70-80 second-line patients will be presented at the upcoming EHA conference on June 12. The treatment was well-tolerated, with no Grade 5 adverse events reported.
Constellation Pharmaceuticals reported its Q1 2020 financial results, highlighting a net loss of $25.4 million, a 31% increase year-over-year.
Cash and cash equivalents totaled $358.8 million, reflecting a 6.5% decline from Q4 2019, primarily due to rising operating expenses in R&D and G&A.
Encouraging data was noted for CPI-0610, with further updates expected at the European Hematology Association conference in June. The company remains focused on advancing clinical trials despite challenges posed by the COVID-19 pandemic.
Constellation Pharmaceuticals (Nasdaq: CNST) announced its participation in two upcoming virtual investor conferences. CEO Jigar Raythatha will speak at the Bank of America Merrill Lynch Global Health Care Conference on May 12 at 9:00 AM EDT and the RBC Capital Markets Global Healthcare Virtual Conference on May 20 at 10:55 AM EDT. Live audio webcasts will be accessible on the company's Investor Relations website, with replays available for 90 days post-event. Constellation focuses on developing therapeutics using epigenetics to treat cancer, including the EZH2 inhibitors CPI-1205 and CPI-0209.